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Abstract
Background: Early kidney transplantation (KT) is the best option for patients with end-stage kidney disease, but
little is known about dialysis access strategy in this context. We studied practice patterns of dialysis access and how
they relate with outcomes in adults wait-listed early for KT according to the intended donor source.
Methods: This study from the REIN registry (2002–2014) included 9331 incident dialysis patients (age 18–69) wait-
listed for KT before or by 6 months after starting dialysis: 8342 candidates for deceased-donor KT and 989 for living-
donor KT. Subdistribution hazard ratios (SHR) of KT and death associated with hemodialysis by catheter or
peritoneal dialysis compared with arteriovenous (AV) access were estimated with Fine and Gray models.
Results: Living-donor candidates used pretransplant peritoneal dialysis at rates similar to deceased-donor KT
candidates, but had significantly more frequent catheter than AV access for hemodialysis (adjusted OR 1.25; 95%CI
1.09–1.43). Over a median follow-up of 43 (IQR: 23–67) months, 6063 patients received transplants and 305 died
before KT. Median duration of pretransplant dialysis was 15 (7–27) months for deceased-donor recipients and 9 (5–
15) for living-donor recipients. Catheter use in deceased-donor candidates was associated with a lower SHR for KT
(0.88, 95%CI 0.82–0.94) and a higher SHR for death (1.53, 95%CI 1.14–2.04). Only five deaths occurred in living-donor
candidates, three of them with catheter use.
Conclusions: Pretransplant dialysis duration may be quite long even when planned with a living donor.
Advantages from protecting these patients from AV fistula creation must be carefully evaluated against catheter-
related risks.
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Background
Among patients with end-stage kidney disease, kidney
transplantation (KT) is associated with improved sur-
vival [1, 2], better quality of life [2, 3], and lower cost [4]
than dialysis. Access to KT is a lengthy process, which
includes assessing patients’ clinical condition and eligi-
bility for KT, their placement on the national transplant
waiting list, and attribution of a graft by the allocation
system (managed in France by the Agence de la Biome-
decine). Except for preemptively transplanted patients,
who account for 4% of the French population treated for
end-stage kidney disease [5], most KT candidates need
dialysis. Although peritoneal dialysis is a valuable modal-
ity for patients awaiting KT [6, 7], hemodialysis is the
modality used by far most frequently in this population,
accounting for 85% of dialyzed patients awaiting KT in
France [8] and in the US [7, 9] and around 67% in
Taiwan [6].
Highly variable fractions of overall KT are planned as
living-donor KT (LDKT) in different countries: 8% of
KT in Finland (3.8 per million population [pmp]), 28%
in the US (17.4 pmp), and 57% in the Netherlands (33.6
pmp) [10, 11]. In France, living donation rates have in-
creased significantly over the past decade rising from 5.1
pmp in 2011 to 8.8 pmp in 2016 [12]. LDKT now ac-
counts for 16% of all KT and is associated with better
patient and graft outcomes than is deceased-donor KT
(DDKT) [2, 13, 14]. Living donation may also provide
more timely access to KT, ideally enabling preemptive
transplantation and thereby avoiding dialysis and its
complications. Nevertheless, most patients require dialy-
sis while on the KT waiting list [15, 16].
Optimizing vascular access is an important challenge
in hemodialysis patients. Guidelines have consistently
recommended placement of an arteriovenous (AV) fis-
tula over AV graft or central venous catheter (CVC) be-
cause the fistula is associated with better outcomes [17,
18]. In response to these recommendations, AV fistula
use has increased substantially over the past decade. The
frequency of percutaneous and surgical interventions to
promote AV fistula maturation and patency has none-
theless increased concurrently [19] Given the burden of
an AV fistula for patients and health resources, nephrol-
ogists may favor other types of vascular access in pa-
tients whose waiting time to KT is expected to be short.
Trends in dialysis access strategies used for patients with
an expected short wait time to kidney transplantation,
i.e., wait-listed early for a living- or deceased-donor kid-
ney, and their impact on outcomes have been poorly
evaluated.
We hypothesized that, in adults wait-listed early for
KT, for whom pretransplant dialysis duration may thus
be expected to be relatively short, there may be a shift
from AV access to CVC use. We used data from the
national REIN registry to study trends in practice pat-
terns of dialysis access in incident patients wait-listed for
KT before or within 6 months after starting dialysis and
further assessed the relation of that access strategy with




The Renal Epidemiology and Information Network
(REIN) registry was set up in 2002 and includes all pa-
tients with end-stage kidney disease who start kidney re-
placement therapy in France [20]. The 9580 patients in
this study were aged 18 to 69 years, had started hemo-
or peritoneal dialysis between January 2002 and Decem-
ber 2014, and were placed on the national KT waiting
list before or within 6months after starting dialysis
(Fig. 1). We excluded 249 patients with information
missing about either first dialysis modality or first dialy-
sis access. Patients were then classified according to
whether they were wait-listed for DDKT only (n = 8342)
or for LDKT (n = 989, including 490 patients simultan-
eously awaiting deceased donation). In France, registra-
tion on the national waiting list is mandatory for all KT
candidates, for either living or deceased donation, and
information about the intended donor type is routinely
recorded.
The REIN registry and its utilization for research pur-
poses have been approved by the relevant French ethics
committees, specifically, the Comité consultatif sur le
traitement de l’information en matière de recherche
(CCTIRS) and the Commission nationale de l’informa-
tique et des libertés (CNIL N° 903,188). French regula-
tions do not require participants’ written or verbal
informed consent for their inclusion in population-based
registries requiring exhaustiveness. Patients are informed
about the registration of all individuals with treated end-
stage kidney disease in the REIN registry by the nephrol-
ogy clinic as well as about their right to not participate
(opt out).
Information
The dialysis access strategy, defined by the combination
of dialysis modality and vascular access type at
hemodialysis initiation (CVC or AV access), was our
main exposure variable, in three classes: hemodialysis
with AV access or with CVC, and peritoneal dialysis. AV
fistulae and AV grafts could not be distinguished at
hemodialysis initiation, but AV graft use has been shown
to be marginal in prevalent hemodialysis patients in
France (about 3%) [21].
Our analyses also considered three categories of base-
line variables. The first category included demographic
data: age, gender, region of residence, and work status
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(in the labor market or not). The second category cov-
ered clinical data: primary kidney disease categorized in
six groups (glomerulonephritis, diabetic nephropathy,
vascular nephropathy, polycystic kidney disease, others,
and unknown primary kidney disease), cardiovascular
comorbidities assessed as a four-level qualitative variable
(0, 1, 2, or ≥ 3 cardiovascular comorbidities among
arrhythmia, coronary artery disease, congestive heart fail-
ure, and cerebrovascular disease), peripheral vascular dis-
ease, diabetes, history of previous transplantation (kidney
graft excluded), and physical disabilities (autonomous ver-
sus partially or totally dependent). Nutritional status was
also assessed through body mass index (categorized as <
18.5 kg/m2, 18.5–24.9, 25–29.9 and ≥ 30) and hypoalbu-
minemia (defined as serum albumin < 30 g/dl). The third
category included data related to the ownership of the
nephrology facility (public university centers, public non-
university centers, private not-for-profit and private-for-
profit centers), and whether dialysis start was planned or
not. Unplanned dialysis start is defined in the registry as
any first dialysis session initiated in life-threatening cir-
cumstances requiring dialysis within 24 h. Blood group (A,
B, AB, and O) and panel reactive antibody level were also
collected. If panel reactive antibody level was ≥85%, the
patient was considered highly sensitized.
In France, any wait-listed patient who is temporary
unavailable or unsuitable for KT is assigned a temporary
inactive status. This status is also applied to patients
wait-listed before a complete final check-up. These pe-
riods of inactive status were also recorded.
Outcomes
The outcome of interest was KT by 31 December 2014,
with death on the waiting list as a competing risk. Time
to event was calculated from listing date or dialysis initi-
ation, depending on whether the patient was preemp-
tively wait-listed or not, to avoid the immortal time bias.
Non-transplanted living patients were censored at the
end of follow-up.
Statistical methods
Patient characteristics at baseline were described for the
two groups, distinguished by whether patients were
wait-listed for deceased-only or living- (with or without
deceased-) donor KT. We also described trends in the
distribution of dialysis access categories between 2006
and 2014 in 11 French regions with full information over
the period. Missing data (Table S1) were imputed with
the fully conditional specification method [22]. In all, 20
imputed data sets were modeled separately and then
combined to take the uncertainty related to the missing
values into account. The imputation model included all
of the variables listed in Table 1, as well as the geo-
graphic region, year of first treatment for end-stage kid-
ney disease, and vital status at the end of follow-up. We
then estimated adjusted multinomial odds ratios (ORs)
for the three dialysis access strategy classes defined
above and stratified by donor type, considering
hemodialysis with AV access as the reference category.
Models were adjusted for gender, age, region, year of
dialysis initiation, occupational activity, primary kidney
Fig. 1 Patient selection. Abbreviations: KT, kidney transplantation
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Table 1 Baseline characteristics of patients according to donor type at wait-listing for kidney transplantation
Characteristics Donor type P-
valueDeceased
(n = 8342, 89%)
Living
(n = 989, 11%)
Men, % 62 64 0.211
Age (years), median (IQR) 51 (41–59) 45 (33–55) < 0.001
Primary kidney disease, % < 0.001
Glomerulonephritis 24 32
Diabetic nephropathy 12 7
Hypertensive or vascular nephropathy 11 8
Polycystic kidney disease 21 17
Others 22 24
Unknown 10 12
Diabetes, % 18 13 < 0.001




≥ 3 0.5 0.4
Peripheral arterial disease, % 5 4 0.208
Mobility status (partially or totally dependent), % 2 1 0.159
Serum albumin (g/dL), mean (SD) 36.0 (6.4) 35.5 (6.5) 0.094
Body mass index (kg/m), % 0.126
< 18.5 7 8
[18.5,25] 47 50
[25, 30] 30 28
≥ 30 16 14
Professionally active, % 51 65 < 0.001
Unplanned dialysis start, % 14 17 0.005
History of previous transplantation (kidney excluded), % 3 2 0.620
Preemptive placement on waiting list, % 47 44 0.055
Temporary inactive status, % 49 54 0.003





PRA level ≥ 85%, % 7 7 0.661
Ownership of nephrology facility, % 0.661
Public non-university centre 21 20
Public university centre (performing KT) 28 29
Private for-profit centre 24 25
Private not-for-profit centre 27 26
Abbreviations: PRA panel reactive antibody, KT kidney transplantation
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disease, history of diabetes, peripheral arterial disease,
previous transplantation (kidney excluded), number of
cardiovascular comorbidities, mobility status, body mass
index, serum albumin, panel reactive antibody level,
blood group, unplanned dialysis start, preemptive place-
ment on waiting list, temporary inactive status, and own-
ership of the nephrology facility.
We used the cumulative incident function, with Gray’s
test, to estimate rates of KT and death according to the
dialysis access strategy, stratified by intended donor type.
The association between dialysis access strategy and out-
comes within each donor group was assessed with a
multivariate Fine and Gray analysis. In the presence of
competing risks, the Fine and Gray approach is the most
appropriate model for prognostic research, to estimate
the probabilities of an event, given patient characteristics
[23]. We estimated crude and adjusted SHRs and 95%
confidence intervals (95% CI). Besides age, gender, dia-
betes, and region (as strata), which were systematically
included in adjusted models, other covariates were se-
lected according to the Bayesian (Schwarz) Information
Criterion. The proportional hazard assumption was
assessed by plotting scaled Schoenfeld residuals versus
rank time, by stratification, or by inclusion of a time ×
covariate interaction when appropriate. Because the
number of deaths before KT was very low in the group
awaiting LDKT, adjusted analysis of mortality was not
performed for this group. P-values < 0.05 were consid-
ered statistically significant. Data were analyzed with
SAS 9.4 (SAS Institute, Cary, NC).
Results
Patient’s characteristics
Patients wait-listed for LDKT were younger and
more likely to be working and to have been regis-
tered with a temporary inactive status than those
wait-listed for DDKT (Table 1). DDKT patients, on
the other hand, had a higher prevalence of
comorbidities.
Trends in dialysis access strategy and association with
donor type
Hemodialysis with AV access was the most common
strategy in the study population, with a frequency
higher among DDKT than LDKT patients — 57% ver-
sus 47%, respectively (Fig. 2). From 2006 through
2014, hemodialysis with CVC steadily increased in
both donor groups, apparently mainly at the expense
of hemodialysis with AV access (Fig. 3). In LDKT pa-
tients, hemodialysis begun with CVC regularly
exceeded initial peritoneal dialysis from 2010 onward.
After adjustment for potential confounders, LDKT
patients were significantly more likely than DDKT
patients to start hemodialysis with a CVC than with
AV access (OR 1.25, 95% CI 1.09–1.43), whereas
peritoneal dialysis use did not differ between the two
donor groups (OR 1.09, 95%CI 0.93–1.28). Supple-
mentary Table S2 reports the odds ratios for each
dialysis access strategy associated with other patient
characteristics.
Fig. 2 Prevalence and multinomial adjusted# odds ratio of dialysis access strategy associated with donor type at placement on the kidney
transplant waiting list. Abbreviations: AV, arteriovenous; OR, odds ratio. #Adjusted for gender, age, region, year of dialysis initiation, occupational
activity, primary renal disease, history of diabetes, peripheral arterial disease, previous transplantation (kidney excluded), number of cardiovascular
comorbidities, mobility status, body mass index, serum albumin, panel reactive antibody level, blood group, unplanned dialysis start, preemptive
placement on waiting list, temporary inactive status, and the ownership of the nephrology facility
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Relation between dialysis access strategy and outcomes,
by donor type
Median (interquartile range) follow-up was 43 (23–67)
months. By the end of the study period, 6063 (65%) patients
had undergone KT and 305 (3%) had died before KT. The
number of events, the median duration of pretransplant
dialysis, the cumulative incidence, and the adjusted SHRs
for each outcome studied, by donor and by dialysis access
strategy, are reported in Table 2. The median (interquartile
range) duration of pretransplant dialysis was 15 (7–27)
months for patients awaiting DDKT and 9 (5–15) months
for those awaiting LDKT; it was significantly related to dia-
lysis access strategy in both DDKT (p-value = 0.001) and
LDKT patients (p = 0.003). Of note, 94% of DDKT and 87%
of LDKT recipients received a graft from the expected type
of donor. LDKT patients had a higher cumulative incidence
of KT than DDKT patients, but this did not vary by dialysis
access strategy. In DDKT patients, however, hemodialysis
CVC use, compared with AV access, was associated with
both a lower probability of KT and a higher probability of
death before KT. No difference was observed in the cumu-
lative incidence of either KT or mortality risk in patients
with AV access and peritoneal dialysis.
Discussion
This national registry-based study shows that in patients
wait-listed early for KT, hemodialysis with AV access
was the most common strategy, but highlights a trend
towards greater use of CVC at dialysis start. LDKT were
more likely to start hemodialysis with a CVC than their
counterparts wait-listed for DDKT; the use of peritoneal
dialysis did not differ between these groups. As ex-
pected, LDKT patients had a shorter median time on
dialysis and a higher cumulative incidence of KT than
DDKT patients, but this difference was not related to
dialysis access strategy in the LDKT group. Inversely, in
the DDKT group, CVC use was associated with a lower
incidence of transplantation and a higher mortality risk
than AV access.
Our findings suggest that the type of kidney donor
envisioned influences vascular access strategy in patients
requiring hemodialysis. While AV fistula is the most
used hemodialysis access in both donor groups, some
nephrologists seem to favor CVC over AV access in pa-
tients awaiting LDKT, who may undergo only short-
term hemodialysis. This strategy was not, however, with-
out risk, since patients with CVC in the DDKT group
Fig. 3 Trends in dialysis access strategy at dialysis initiation according to donor type at placement on the kidney transplantation waiting list.
Abbreviation: AV, arteriovenous
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had higher mortality. We cannot draw this conclusion
for the LDKT group, because of the low number of
events. Our results highlight current practices in a pa-
tient situation that may represent a “gray zone”, with
very little evidence about the benefit/risk ratio of differ-
ent types of vascular access.
Several recent studies have challenged the Fistula First
paradigm in hemodialysis patients in terms of survival
[24–26], primary patency [27, 28], and cost-effectiveness
[29, 30]. Findings from these studies provide further evi-
dence in favor of a more patient-centered approach in vas-
cular access choice, one that takes into account the
likelihood of AV fistula maturation, the use of previous
vascular accesses, the patient’s life expectancy, and their
quality of life [31–34]. Nevertheless, attention has focused
mainly on the choice between AV fistula and AV graft in
the elderly, for whom catheter dependency is often an ad-
verse outcome. Preference for an AV fistula has never or
rarely ever been called into question in young adult pa-
tients with low comorbidity profiles, who might have high
probability of AV fistula maturation, but also of trans-
plantation. Woo & Lok [35] discussed the importance of
an end-stage kidney disease life plan in choosing vascular
access and suggested that peritoneal dialysis might be the
best option for patients anticipating an LDKT. Neverthe-
less, our study shows that LDKT patients were not more
likely than those awaiting DDKT to choose peritoneal dia-
lysis. Hemodialysis remains the main dialysis modality in
this population, and their optimal vascular access strategy
has not been investigated so far.
Our study of wait-listed adults indicates that the
hemodialysis duration envisioned may influence vascular
access strategy. When no potential living donor is avail-
able, hemodialysis duration is expected to be longer even
in patients wait-listed early for KT as in this study. Using
donor type as a surrogate, we observed that patients
awaiting LDKT — and thus expecting a relatively short
duration of hemodialysis — were more likely to receive
CVC than DDKT patients were, although the rate of
peritoneal dialysis did not differ between the two donor
types. These results may suggest a potential hemodialysis
access strategy that allows more liberal use of CVC in
patients with anticipated LDKT to preserve their vascu-
lar capital in case of kidney transplant failure. Yet, AV
access was the most frequent type of vascular access in
both groups, used in 47% of those wait-listed for LDKT
and 57% for DDKT.
In a single-center 14-year retrospective cohort of chil-
dren and adolescents, Merouani et al. [36] observed a sub-
stantial decrease in AV fistula use from 76% before the
introduction of pediatric prioritization in graft allocation
in Canada to 41% afterwards. Reasons for this shift from
AV fistula to CVC in children, besides the high rates of
KT and the switch to peritoneal dialysis, may include the
difficulty in obtaining a patent fistula and the avoidance of
access-related steal syndrome and congestive heart failure
[36, 37]. Most of these aspects may also be relevant for
adults wait-listed for LDKT. Moreover, patient reluctance
about or refusal of an AV fistula may account for a signifi-
cant portion of CVC use [38].
Table 2 Number of events, time on dialysisa, 1- and 2-year cumulative incidence, and adjusted subdistribution hazard ratios of
kidney transplantation and death before KT, by donor group




















Number of events 3172 1157 1148 262 205 119
Median time on dialysisa (IQR), months 14.8 (7.4–26.5) 15.9 (8.3–27.6) 13.6 (7.0–25.1) 8.9 (5.6–17.3) 7.5 (4.3–12.0) 9.7 (5.1–16.4)
1-year cumulative incidence (IQR), % 10 (9–10) 4 (3–4) 14 (13–16) 26 (23–30) 27 (24–30) 30 (25–36)
Adjustedb SHR (95% CI) Reference 0.88 (0.82–0.94) 1.01 (0.94–1.09) Reference 1.18 (0.95–1.45) 0.93 (0.72–1.19)
Death before KT
Number of events 149 107 44 0 3 2
Median time on dialysisa (IQR), months 26.9 (11.1–41.7) 19.2 (7.6–36.5) 22.2 (15.8–37.8) – 20.2 (16.5–26.1) 7.1 (7.1–13.4)
1-year cumulative incidence (IQR), % 5 (5–5) 14 (13–14) 6 (5–7) – 0 0.4 (0.04–1.9)
Adjustedc SHR (95% CI) Reference 1.53 (1.14–2.04)d 1.12 (0.80–1.56)d – – –
aIn patients who had the event
bSubdistribution hazard ratios of kidney transplantation were adjusted for gender, age, region (as strata), year of dialysis initiation, history of diabetes, peripheral
arterial disease, serum albumin, panel reactive antibody level, blood group, temporary inactive status, and ownership of the nephrology facility
cSubdistribution hazard ratios of death before kidney transplantation included a time interaction term for dialysis modality and were adjusted for gender, age,
region (as strata), history of diabetes, peripheral arterial disease, previous transplantation (kidney excluded), number of cardiovascular comorbidities (as strata),
mobility status, and serum albumin. These were not estimated for the group awaiting living-donor kidney transplant because of the small number of events
dHazard ratio at 12 months of follow-up
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Nonetheless, although time on hemodialysis await-
ing KT was, as hypothesized, shorter among LDKT
than DDKT patients, these durations of pretransplant
hemodialysis remained substantial. In our study, a
median dialysis duration of 8 to 10 months was seen
in LDKT candidates, and often more than 14 months
in DDKT candidates. Hemodialysis duration may not
be as short as initially expected, and prolonged CVC
use may place patients at increased risk of death as
they await KT. In our study, the SHR of death asso-
ciated with CVC in the DDKT group was 1.53
(95%CI 1.14–2.04).
In a recent cohort study, Kim et al. [39] hypothesized
that a short dialysis period before LDKT would yield re-
sults similar to those of preemptive KT. Their purpose
was also to validate a cutoff value for duration of pre-
transplant dialysis to differentiate clinical outcomes.
After evaluating the outcomes of LDKT according to
this duration in both unmatched and propensity-score-
matched cohorts, they found no difference in either
mortality or death-censored graft survival between recip-
ients of preemptive and non-preemptive KT who had
pretransplant dialysis durations < 19months. Patient sur-
vival was worse, however, when pretransplant dialysis
duration was 19months or longer in a propensity-score-
matched LDKT cohort. On the other hand, Goto et al.
[40] demonstrated that preemptive KT was associated
with a reduced rate of clinical events including mortality,
graft failure and post-transplant cardiovascular disease
(3.3%), while this event rate was significantly higher
among those with a pretransplant dialysis duration < 1
year (10.8%). Similarly, Prezelin-Reydit et al. [41] re-
cently showed that preemptive KT was strongly associ-
ated with a lower hazard of graft failure than
pretransplant dialysis (HR 0.57 95%CI 0.51–0.63), re-
gardless of its duration — even only 6 months. Their
study did not consider the type of vascular access.
Our findings are consistent with the extensive lit-
erature on vascular access outcomes, which points to-
ward an association between CVC use and poor
outcomes. CVC has been associated with higher risk
of mortality [26, 42] and of infectious and non-
infectious complications [26, 43] than either AV fis-
tula or graft. It has also been shown to be the least
cost-effective vascular access for hemodialysis when
either the burden of hospitalization [29] or quality of
life [30] is considered. These results from observa-
tional studies, taken together, have formed the basis
of current vascular access guidelines and the Fistula
First, Catheter Last Initiative. Although the impact of
residual confounding on assessment of vascular access
outcomes is a subject of growing concern [24, 26,
30], the vascular access strategy in our population of
KT candidates is unlikely to be driven by short life
expectancy. Nevertheless, the relative survival benefit
associated with AV fistula in our study should be
seen in the perspective of the very low mortality rates
of patients wait-listed for KT. Other outcomes related
to vascular access strategy, such as access function,
morbidity, quality of life, and cost-effectiveness,
should be evaluated in this population [44, 45].
Major strengths of this study include the size and
unselected nature of our registry-based population.
We adjusted our analysis for several potential con-
founders that might affect either vascular access
choice or access to KT, such as unplanned dialysis
start, panel reactive antibody level, and temporary in-
active status. Some of these factors were also inde-
pendent predictors of mortality. We also applied an
alternative method that takes into account the com-
peting risk of death before transplantation. Conven-
tional methods such as the Kaplan-Meier method and
standard Cox proportional hazards regression may be
inappropriate in the presence of competing risks,
which may hinder the observation of the event of
interest. In this case, an adjusted subdistribution haz-
ards approach has been shown to be most appropriate
for prognostic research [23].
Our study also has limitations. First, due to the obser-
vational nature of the study, the results can only describe
associations; causality cannot be inferred. Second, LDKT
accounts for highly variable portions of KT among coun-
tries, and national allocation policies may have a sub-
stantial impact on waiting-list time. Our results may
thus be specific to certain contexts. Third, the small
number of adverse events in the LDKT group highlights
the need for dedicated cohort studies focused on dialysis
access for these patients.
Conclusions
Our study shows that vascular access strategy differs ac-
cording to whether hemodialysis patients were wait-
listed for living- or deceased-donor KT. Although AV
fistula was the most frequently used dialysis access in
the study population, some nephrologists tended to favor
CVC over AV fistula to start hemodialysis in patients
awaiting living donation, likely because they expect the
duration of dialysis to be short. Although this strategy
may protect these patients from AV fistula creation and
its potential drawbacks, known complications of CVC
(such as infections and thrombosis) we indicate the need
for caution. Given the difficulty of predicting pretrans-
plant hemodialysis duration, the risk of complications
from long-term CVC use must be carefully evaluated.
More studies are required to clarify the benefit/risk ratio
of dialysis access strategy for non-fatal outcomes among
KT candidates.
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